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Abstract 
Since hepatitis C virus (HCV) and human T-lymphotropic virus (HTLV) share 
transmission routes, dual infection could be frequent. In Spain, HTLV underdiagnosis 
is highlighted by the high proportion of patients presenting either with tropical spastic 
paraparesis (TSP) or adult T-cell leukemia (ATL) at first diagnosis. We examined 
whether the renewed efforts for expanding HCV testing may provide a sentinel 
population that might selectively be targeted to unveil asymptomatic HTLV carriers. 
The presence of anti-HTLV antibodies was examined in 3,838 consecutive 
individuals with reactive HCV serology attended during the last three years at 13 
hospitals distributed across the Spanish geography. Overall 71% were male and the 
median age was 41-years old. Foreigners represented 9% of the study population. A 
total of 50 individuals (1.3%) were seroreactive for HTLV, being 30 confirmed as 
HTLV-2 and two as HTLV-1 (0.12%). The remaining 18 had indeterminate Western 
blot patterns. Most individuals with HTLV-2 and HTLV indeterminate serology were 
HIV-positive, former injection drug users and native Spaniards. In contrast, the two 
HTLV-1 infections were found in men coming from Brazil and the Dominican 
Republic, respectively. In summary, the overall prevalence of HTLV infection in 
individuals living in Spain seropositive for HCV is 1.3%, more than 10-fold greater 
than in general outclinics in Spain. However, immigrants from HTLV-1 endemic 
regions and former injection drug users with HTLV-2 infection are by far the major 
contributory groups in HCV patients. Therefore, testing for HTLV in newly diagnosed 
HCV individuals would not contribute much to improve late HTLV diagnosis in Spain. 
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Introduction 
Human T-lymphotropic virus type 1 (HTLV-1) infection is a neglected disease despite 
affecting more than 10 million people worldwide.1,2 Lifelong nearly 10% of HTLV-1 
carriers may develop clinical manifestations, including two life-threatening illnesses, 
namely a subacute invalidating myelopathy known as tropical spastic paraparesis 
(TSP)3 and a malignant acute T-cell leukemia/lymphoma (ATL).4 There are highly 
endemic regions for HTLV-1 infection in South Japan, Iran, Papua New Guinea, Sub-
Saharan Africa, South America and the Caribbean basin.1,2 HTLV-1 infection is rather 
rare among native Europeans but in Romania. However, the rate of infection in 
Europe has been on the rise during the last decades among immigrants from 
endemic areas, travellers and their sexual contacts.5,6 In contrast, HTLV-2, which is 
rarely pathogenic, has been circulating among injection drug users in Europe and 
North America for long time.7,8
As HTLV-1, hepatitis C virus (HCV) is a blood-borne pathogen. Not surprisingly, both 
HTLV and HCV are more often diagnosed in persons infected with other viruses 
having overlapping transmission routes, such as human immunodeficiency virus 
(HIV) or hepatitis B virus (HBV).9,10 In contrast with retroviruses and HBV, 
transmission of HCV is uncommon throughout sexual contact,11,12 although recent 
outbreaks of acute hepatitis C among homosexual men have changed this view.13 
The natural history of chronic hepatitis C is well known to be accelerated in patients 
coinfected with HIV and/or hepatitis B, at least in part due to persistent immune 
activation and chronic inflammation.14,15 In contrast, there is limited information on 
the rate of HCV and HTLV coinfection, and particularly on the influence of HTLV on 
HCV-related liver disease progression or treatment outcomes.16-22 In Spain, HTLV 
underdiagnosis is highlighted by the high proportion of first diagnosis presenting with 
either TSP or ATL.6  
The recent recommendation for expanding HCV screening,23 in order to unveil the 
large number of people unaware of their hepatitis C that could benefit from new 
antiviral therapies, may provide a unique opportunity for identifying a sentinel group 
in which HTLV testing might be cost-effective. In this study we assessed the 
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prevalence of antibodies to HTLV-1/2 in a large and representative group of 
individuals HCV-seropositive living in Spain. 
PATIENTS AND METHODS 
All 45 clinics belonging to the HTLV Spanish network were invited to participate in the 
survey in year 2012. The study was designed as a cross-sectional blinded analysis of 
all HCV-antibody positive individuals consecutively attended at the different settings 
distributed across the Spanish geography. The study obtained approval from the 
corresponding hospital ethics committees. Along with serum storage, main 
demographics including age, gender, HIV status, risk behaviour, and country of origin 
were collected in a case report form specially designed for this study. 
Anti-HTLV antibodies were tested using either a commercial enzyme immunoassays 
(EIA) (Murex HTLV I+II; Diasorin, Madrid, Spain) or a chemiluminescent microparticle 
immunoassay (Architect, rHTLV-I/II, Abbott, Chicago, IL). EIA testing was carried out 
in pools of five sera, a step previously shown to preserve sensitivity and improve 
specificity.24 Sera from reactive pools were re-tested individually and further 
confirmed and typed using Western blot (Bioblot HTLV, Genelabs, Singapore). 
Interpretation was made following the HTLV Blot 2.4 interpretation criteria.25 Data 
from medical records were recovered for all subjects HTLV-seropositive. 
Anti-HCV antibodies had been tested using distinct commercial EIAs and serum 
HCV-RNA had been measured using a PCR assay (Roche, Madrid, Spain).    
Statistical analysis. All results are given as absolute values or proportions, and 
mean or median values. Comparisons were made using the chi square test, with 
Fisher correction when appropriated. Differences were considered to be significant 
only when p values were lower than 0.05. All analyses were performed using SPSS 
version 15.0.  
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RESULTS 
From January 2013 to December 2015, a cross-sectional blinded study was 
conducted in all HCV-antibody positive individuals consecutively attended at 13 
different settings distributed across the Spanish geography. A total of 3,838 HCV-
seroreactive individuals were tested for HTLV antibodies. Table 1 summarizes the 
most relevant features of the study population. Clinics contributing actively to the 
survey were distributed across the whole Spanish geography, including the Canary 
islands. Mean age was 41 years-old and 71% were male. The majority were native 
Spaniards (91%), being the rest foreigners coming from other European countries 
(3.2%), Latin America (2%) and Africa (1.8%). The most likely route of HCV 
acquisition was needle exchange in injection drug users (67%), sex in gay men 
(17%), heterosexual contact (9%) and transfusions (2.9%). 
HCV genotype could be characterized in 955 viremic individuals. By far, genotype 1 
was the most frequent (66%), followed by genotype 3 (17.5%), genotype 4 (13.6%) 
and genotype 2 (2.9%). Finally, coinfection with HIV-1 could be investigated in 1,284 
patients, being positive in 345 (26.8%). 
Overall 50 individuals (1.3%) were EIA or CMIA reactive for HTLV. Western blot 
confirmed 2 as HTLV-1 positive and 30 as HTLV-2 positive. The remaining 18 
samples repeatedly depicted indeterminate Western blot profiles. Given the blinded 
nature of the study, a second blood sample could not be obtained for further PCR 
examination in peripheral blood mononuclear cells. Of note, HTLV-seroreactive 
cases were widely distributed across the Spanish geography, with no evidence of 
clusters or links between them. 
HTLV-1 infections were found in a 50 years-old male immigrant from the Dominican 
Republic. Most likely he had acquired the infection in his country of origin through 
heterosexual contacts. The second HTLV-1 carrier was a 49 years-old male born in 
Brazil and coinfected with HIV-1. None complained signs or symptoms potentially 
associated to HTLV-1 infection at the time of diagnosis. In contrast, HTLV-2 and 
HTLV-indeterminate individuals were mostly native Spaniards, being the only 
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exceptions from Italy, Portugal and Germany (one each). Most of them were former 
injection drug users and more than half were HIV-positive (Table 2). 
DISCUSSION 
The overall prevalence of HTLV infection in HCV-seropositive persons in Spain was 
1.3% in our study, more than 10-fold higher than in the general population attended 
in outclinics.26 However, it should be highlighted that HTLV-1 only was found among 
foreigners coming from endemic countries in Latin America whereas HTLV-2 was 
mostly found in native Spaniards with history of prior injection drug use, being most 
of them coinfected with HIV-1. Our results suggest that HCV-seroreactivity is a weak 
surrogate for HTLV-1 infection in Spain and that immigration from highly HTLV-1 
endemic areas should be the major alert for unveiling the diagnosis of asymptomatic 
HTLV-1 carriers. Our data are in agreement with results from prior smaller surveys.27-
29
Overall 50 individuals (1.3%) were reactive for HTLV in screening assays. Western 
blot confirmed 2 as HTLV-1 positive and 30 as HTLV-2 positive. The remaining 18 
samples repeatedly depicted indeterminate Western blot profiles, as previously 
reported in HIV-infected injection drug users that were later confirmed mostly as 
HTLV-2.30 Overall, 13 of our 18 Western blot indeterminate specimens belonged to 
former injection drug users, and 10 were HIV-positive. Given the blinded nature of 
the study, a second blood sample could not be obtained for further PCR examination 
in peripheral blood mononuclear cells. 
Roughly 75% of individuals exposed to HCV develop chronic infection and become at 
risk for developing liver cirrhosis and occasionally hepatocellular carcinoma. 
Worldwide 80 million people are estimated to suffer from chronic HCV infection. In 
most Western countries, chronic hepatitis C is the major cause for liver 
transplantation.11 HTLV co-infection may enhance HCV replication and viral load, 
leading to lower HCV sustained virological response to interferon-α treatment, and 
influencing HCV liver disease progression.17-22 On the other hand, no data exist on 
the potential influence of HCV on HTLV pathogenicity. Hypothetically, immune 
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activation and chronic inflammation driven by persistent replication of one virus may 
provide a continuous stimulus for replication of other co-existing viruses, as already 
being demonstrated in the HIV setting.31 
A national registry of HTLV-1 and HTLV-2 cases exists in Spain since 1988, when 
the first individuals with HTLV-1 infection were reported.6,32 A total of 327 cases of 
HTLV-1 had been diagnosed until the end of 2016. Overall, 62% were immigrants 
from Latin America and 13% came from Africa, being only 19% native Spaniards. 
Males were 39% and mean age at diagnosis was 41 years-old. Symptomatic HTLV-1 
infections had been diagnosed in 58 individuals (18%), being TSP in 33 and ATL in 
25 patients. New diagnoses of HTLV-1 infection have risen sharply in Spain since 
2008, largely as result of broader HTLV screening in blood banks and the growing 
arrival of immigrants.33 
On the other hand, a total of 793 cases of HTLV-2 infection had been reported in 
Spain up to December 2016. In contrast with HTLV-1 persons, HTLV-2 carriers are 
mostly native Spaniards (91%), males (76%), former injection drug users (78%) and 
frequently coinfected with HIV-1 (85%). The number of reported cases of HTLV-2 has 
been steadily declining in Spain since year 2002, mostly reflecting reduced injection 
drug use behaviors.34  
In Spain, HTLV underdiagnosis is highlighted by the high proportion of first diagnosis 
presenting either TSP or ATL.6 Given that HCV and HTLV share transmission routes, 
dual infection could be particularly frequent. In the current study, we examined 
whether the renewed efforts for expanding HCV testing for antiviral curative purposes 
may provide a unique sentinel population that might selectively be targeted to unveil 
asymptomatic HTLV carriers. The presence of anti-HTLV antibodies was examined in 
3,838 consecutive individuals with reactive HCV serology attended during the last 
three years. The overall prevalence of HTLV infection was 1.3%, more than 10-fold 
greater than in the general Spanish outpatient population.26 However, immigrants 
from HTLV-1 endemic regions and former injection drug users with HTLV-2 infection 
were the major contributory risk groups in HCV patients. Therefore, our results 
suggest that HTLV testing of HTLV newly diagnosed HCV individuals would not 
contribute much to improve late HTLV diagnosis. 
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At this time, HTLV screening of first donors in blood banks, pregnant women35 and 
donor-recipient transplants36 seem to be the most cost-effective strategies to identify 
asymptomatic HTLV-1 carriers in Spain. People coming from HTLV-1 endemic 
regions, their sexual contacts or children are overrepresented among newly 
diagnosed HTLV-1 individuals in any of these groups. Since HTLV-1-infected 
mothers may largely prevent transmission to their newborns avoiding breastfeeding37 
and TSP may develop more frequently and rapidly in transplant recipients,38-40 it 
seems worth to recommend universal HTLV screening of at least these two groups in 
Spain, where there immigrants from endemic regions, mostly Latin America, 
represents a large population. In blood banks, the introduction of leukoreduction 
procedures drastically minimizes the risk of HTLV transmission;41 however, universal 
HTLV screening of first donors perhaps using pools may still be a cost-effective 
strategy. From our study, we conclude that HCV is a weak surrogate for HTLV-1 
infection and that immigration from highly HTLV-1 endemic areas should be the 
major target for unveiling asymptomatic carriers. In other words, HTLV testing of 
newly diagnosed HCV individuals would not contribute much to improve late HTLV 
diagnosis. 
_________________________ 
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Guardia & E. do Pico (ICS, Barcelona); I. Polo, A. Aguinaga & C. Ezpeleta (Complejo 
Hospitalario Navarra, Pamplona); S. Sauleda & M. Pirón (Banco de Sangre & 
Tejidos, Barcelona); P. Torres, R. González (Centro de Transfusiones, Madrid); A. 
Jiménez & L. Blanco (Centro de Hemoterapia y Hemodonación de Castilla y León, 
Valladolid); A. Suárez & I. Rodríguez-Avial (Hospital Clínico San Carlos, Madrid); A. 
Pérez-Rivilla, P. Parra & M. Fernández (Hospital Universitario 12 de Octubre, 
Madrid); A. Treviño, S. Requena, I. Carrasco, M. Hernández, L. Benítez-Gutiérrez, V. 
Cuervas-Mons & C. de Mendoza (IIS Hospital Universitario Puerta de Hierro, 
Majadahonda); P. Barreiro & V. Soriano (Hospital Universitario La Paz, Madrid). 
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Table 1. Main characteristics of the HCV study population. 
No. 3,838 
Male (%) 71 
Median age (IQR), years 41 (31-57) 
Origin (%) 
  Native Spaniards 
  Latin America 
  Africa 
  East Europe 
  West Europe 
91 
2 
1.8 
1.3 
1.9 
Risk group (%) 
  Injection drug use 
  Men who have sex with men 
  Heterosexual contact 
  Transfusion 
  Others 
67 
17 
9 
2.9 
3 
HCV genotypes (%) 
  1 
  2 
  3 
  4 
66 
2.9 
17.5 
13.6 
15 
15 
H
T
L
V
 i
n
fe
ct
io
n
 i
n
 H
C
V
-a
n
ti
b
o
d
y
 p
o
si
ti
v
e 
p
at
ie
n
ts
 i
n
 S
p
ai
n
 (
d
o
i:
 1
0
.1
0
8
9
/A
ID
.2
0
1
6
.0
3
2
3
) 
T
h
is
 p
ap
er
 h
as
 b
ee
n
 p
ee
r-
re
v
ie
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
li
ca
ti
o
n
, 
b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
g
o
 c
o
p
y
ed
it
in
g
 a
n
d
 p
ro
o
f 
co
rr
ec
ti
o
n
. 
T
h
e 
fi
n
al
 p
u
b
li
sh
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
Table 2. Main characteristics of the HTLV population. 
No. HTLV-1+ 
 (n=2) 
HTLV-2+ 
(n=30) 
HTLV indeterminate 
(n=18) 
Male 1 24 13 
Country of origin Dominican Republic (1) 
Brazil (1) 
Spain (29) 
Germany (1) 
Spain (14) 
Italy (1) 
Portugal (1) 
Unknown (2) 
Risk group Birth in endemic regions (2) IDU (24) IDU (12) 
HTSEX (1) 
HCV genotype G2 (1) 
Unknown (1) 
G1 (7) 
G3 (3) 
Unknown (20) 
G1 (4) 
Unknown (14) 
HIV-1 coinfection 1 21 10 
IDU, injection drug use; HTSEX, heterosexual 
